Data from Haplotype Analysis of the <i>HSD17B1</i> Gene and Risk of Breast Cancer: A Comprehensive Approach to Multicenter Analyses of Prospective Cohort Studies

<div>Abstract<p>The 17β-hydroxysteroid dehydrogenase 1 gene (<i>HSD17B1</i>) encodes 17HSD1, which catalyzes the final step of estradiol biosynthesis. Despite the important role of <i>HSD17B1</i> in hormone metabolism, few epidemiologic studies of <i>HSD17B1</i> and breast cancer have been conducted. This study includes 5,370 breast cancer cases and 7,480 matched controls from five large cohorts in the Breast and Prostate Cancer Cohort Consortium. We characterized variation in <i>HSD17B1</i> by resequencing and dense genotyping a multiethnic sample and identified haplotype-tagging single nucleotide polymorphisms (htSNP) that capture common variation within a 33.3-kb region around <i>HSD17B1</i>. Four htSNPs, including the previously studied SNP rs605059 (<i>S312G</i>), were genotyped to tag five common haplotypes in all cases and controls. Conditional logistic regression was used to estimate odds ratios (OR) for disease. We found no evidence of association between common <i>HSD17B1</i> haplotypes or htSNPs and overall risk of breast cancer. The OR for each haplotype relative to the most common haplotype ranged from 0.98 to 1.07 (omnibus test for association: <i>X</i><sup>2</sup> = 3.77, <i>P</i> = 0.58, 5 degrees of freedom). When cases were subdivided by estrogen receptor (ER) status, two common haplotypes were associated with ER-negative tumors (test for trend, <i>P</i>s = 0.0009 and 0.0076; <i>n</i> = 353 cases). <i>HSD17B1</i> variants that are common in Caucasians are not associated with overall risk of breast cancer; however, there was an association among the subset of ER-negative tumors. Although the probability that these ER-negative findings are false-positive results is high, these findings were consistent across each cohort examined and warrant further study. (Cancer Res 2006; 66(4): 2468-75)</p></div>